Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or “naked” form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action.
We have exclusively licensed our lead product candidate, Epratuzumab, to UCB for the treatment of all non-cancer indications worldwide. Epratuzumab is currently in two Phase III pivotal trials for the treatment of patients with moderate or severe systemic lupus erythematosus (SLE) or lupus. We have also licensed the exclusive worldwide right to develop the subcutaneous formulation of Veltuzumab for all non-cancer indications to Nycomed, who is pursuing a rheumatoid arthritis indication in a Phase II clinical trial.
We are conducting clinical trials with yttrium-90-labeled (90Y) Clivatuzumab for pancreas cancer therapy, Veltuzumab combined with 90Y Epratuzumab in patients with non-Hodgkin's lymphoma, Milatuzumab and Veltuzumab as therapies for patients with chronic lymphocytic leukemia. We also have two antibody-drug conjugate (ADC) agents in the clinic. Our first ADC is milatuzumab-doxorubicin, which is in a Phase 1 study in patients with relapsed multiple myeloma. Another ADC, labetuzumab-SN-38, is in a dose-escalation study in patients with colorectal cancer.
In addition to our potential therapeutic products, our proprietary technologies have also enabled us to develop highly specific diagnostic imaging agents, one of which, LeukoScan®, has been approved in Europe, Canada, Australia, and certain other countries, where it is currently being marketed for the detection of bone infections. We also market ImmuSTRIP® for the detection of human anti-murine antibodies or HAMA in patients who may have pre-existing HAMA or have developed HAMA from treatment with murine (mouse) monoclonal antibody products.
We have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. TF2 is our first DNL-derived product currently in early-stage clinical evaluation as a pretargeted radiation therapy in patients with advanced colorectal cancer.